QuiaPEG Pharmaceuticals Holding AB (publ) (QUIA.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 26.7 Million SEK | 27.0% |
| 2022 | 21.03 Million SEK | -11.42% |
| 2021 | 23.74 Million SEK | 15.98% |
| 2020 | 20.47 Million SEK | -13.92% |
| 2019 | 23.78 Million SEK | 170.78% |
| 2018 | 8.78 Million SEK | 31.35% |
| 2017 | 6.68 Million SEK | 83.23% |
| 2016 | 3.64 Million SEK | 86.27% |
| 2015 | 1.95 Million SEK | -49.63% |
| 2014 | 3.88 Million SEK | -8.52% |
| 2013 | 4.25 Million SEK | -44.84% |
| 2012 | 7.7 Million SEK | 127.08% |
| 2011 | 3.39 Million SEK | 25.38% |
| 2010 | 2.7 Million SEK | -4.98% |
| 2009 | 2.84 Million SEK | -17.66% |
| 2008 | 3.46 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 7.89 Million SEK | 0.0% |
| 2024 Q1 | 7.89 Million SEK | -70.46% |
| 2023 Q1 | 15.84 Million SEK | -24.66% |
| 2023 Q2 | 15.84 Million SEK | 0.0% |
| 2023 Q3 | 26.7 Million SEK | 68.57% |
| 2023 Q4 | 26.7 Million SEK | 0.0% |
| 2023 FY | 26.7 Million SEK | 27.0% |
| 2022 Q4 | 21.03 Million SEK | 4.46% |
| 2022 FY | 21.03 Million SEK | -11.42% |
| 2022 Q1 | 24.81 Million SEK | 4.54% |
| 2022 Q2 | 18.93 Million SEK | -23.69% |
| 2022 Q3 | 20.13 Million SEK | 6.3% |
| 2021 Q4 | 23.74 Million SEK | -3.71% |
| 2021 Q3 | 24.65 Million SEK | 7.92% |
| 2021 Q2 | 22.84 Million SEK | 28.09% |
| 2021 Q1 | 17.83 Million SEK | -12.87% |
| 2021 FY | 23.74 Million SEK | 15.98% |
| 2020 Q4 | 20.47 Million SEK | -2.99% |
| 2020 Q2 | 34.42 Million SEK | 31.1% |
| 2020 Q3 | 21.1 Million SEK | -38.7% |
| 2020 Q1 | 26.25 Million SEK | 10.42% |
| 2020 FY | 20.47 Million SEK | -13.92% |
| 2019 Q2 | 8.57 Million SEK | -19.03% |
| 2019 Q4 | 23.78 Million SEK | 7.6% |
| 2019 FY | 23.78 Million SEK | 170.78% |
| 2019 Q1 | 10.58 Million SEK | 20.54% |
| 2019 Q3 | 22.1 Million SEK | 157.83% |
| 2018 Q3 | 8.03 Million SEK | 2.72% |
| 2018 FY | 8.78 Million SEK | 31.35% |
| 2018 Q4 | 8.78 Million SEK | 9.36% |
| 2018 Q2 | 7.81 Million SEK | 17.9% |
| 2018 Q1 | 6.63 Million SEK | -0.84% |
| 2017 FY | 6.68 Million SEK | 83.23% |
| 2017 Q1 | 16.78 Million SEK | 360.04% |
| 2017 Q2 | 6.37 Million SEK | -62.01% |
| 2017 Q3 | 8.69 Million SEK | 36.27% |
| 2017 Q4 | 6.68 Million SEK | -23.07% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 3.64 Million SEK | 86.27% |
| 2016 Q2 | 1.72 Million SEK | 0.0% |
| 2016 Q3 | - SEK | -100.0% |
| 2016 Q4 | 3.64 Million SEK | 0.0% |
| 2015 Q4 | 1.95 Million SEK | 0.0% |
| 2015 FY | 1.95 Million SEK | -49.63% |
| 2015 Q2 | 2.35 Million SEK | 0.0% |
| 2014 FY | 3.88 Million SEK | -8.52% |
| 2014 Q4 | 3.88 Million SEK | 0.0% |
| 2014 Q2 | 4.43 Million SEK | 0.0% |
| 2013 FY | 4.25 Million SEK | -44.84% |
| 2013 Q2 | 3.55 Million SEK | 0.0% |
| 2013 Q4 | 4.25 Million SEK | 0.0% |
| 2012 FY | 7.7 Million SEK | 127.08% |
| 2012 Q4 | 7.7 Million SEK | 0.0% |
| 2012 Q2 | 4.31 Million SEK | 0.0% |
| 2011 Q2 | 3.15 Million SEK | 0.0% |
| 2011 FY | 3.39 Million SEK | 25.38% |
| 2010 Q2 | 2.62 Million SEK | 0.0% |
| 2010 FY | 2.7 Million SEK | -4.98% |
| 2009 FY | 2.84 Million SEK | -17.66% |
| 2008 FY | 3.46 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 74.944% |
| Ziccum AB (publ) | 6.38 Million SEK | -318.096% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -1032.175% |
| BioArctic AB (publ) | 139.5 Million SEK | 80.855% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 22.816% |
| Mendus AB (publ) | 51.22 Million SEK | 47.861% |
| Genovis AB (publ.) | 98.04 Million SEK | 72.76% |
| Intervacc AB (publ) | 21.68 Million SEK | -23.192% |
| Active Biotech AB (publ) | 13.4 Million SEK | -99.313% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 78.458% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -65.713% |
| Aptahem AB (publ) | 8.99 Million SEK | -196.827% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 34.634% |
| Kancera AB (publ) | 17.97 Million SEK | -48.559% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 42.165% |
| Fluicell AB (publ) | 8.91 Million SEK | -199.585% |
| Saniona AB (publ) | 86.08 Million SEK | 68.974% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -417.798% |
| Biovica International AB (publ) | 34.76 Million SEK | 23.18% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -128.9% |
| AcouSort AB (publ) | 10.37 Million SEK | -157.352% |
| Xintela AB (publ) | 14.01 Million SEK | -90.567% |
| Abliva AB (publ) | 16.78 Million SEK | -59.156% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 87.555% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -130.858% |
| OncoZenge AB (publ) | 1.69 Million SEK | -1471.984% |
| Amniotics AB (publ) | 10.54 Million SEK | -153.228% |
| 2cureX AB (publ) | 2.93 Million SEK | -809.983% |
| CombiGene AB (publ) | 4.15 Million SEK | -542.637% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -503.434% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 98.294% |
| Camurus AB (publ) | 414.81 Million SEK | 93.562% |
| Corline Biomedical AB | 6.78 Million SEK | -293.401% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 56.471% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -39.365% |
| I-Tech AB | 16.2 Million SEK | -64.813% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 97.748% |
| Cyxone AB (publ) | 4.69 Million SEK | -468.982% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -100.39% |
| Biosergen AB | 5.08 Million SEK | -425.231% |
| Cantargia AB (publ) | 54.97 Million SEK | 51.413% |
| NextCell Pharma AB | 13.68 Million SEK | -95.105% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 62.828% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -93.936% |
| Nanologica AB (publ) | 79.32 Million SEK | 66.332% |
| SynAct Pharma AB | 51.83 Million SEK | 48.474% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -235.992% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -414.115% |
| LIDDS AB (publ) | 3.75 Million SEK | -611.076% |
| Lipum AB (publ) | 7.53 Million SEK | -254.311% |
| BioInvent International AB (publ) | 90.45 Million SEK | 70.473% |
| Alzinova AB (publ) | 9.33 Million SEK | -186.229% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 85.293% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -1388.74% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -44.414% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -595.883% |
| Simris Alg AB (publ) | 148.93 Million SEK | 82.068% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 62.446% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 94.461% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -109.573% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -267.879% |